Bristol-Myers Squibb (BMY) AI Stock Analysis

• Market Cap: $0.00
• Dividend Yield: 5.37%
• Average Volume (3M): 13.26M
• Price to Earnings (P/E): 18.3
• Beta (1Y): 0.00
• Revenue Growth: 2.57%
• EPS Growth: N/A
• Country: US
• Employees: 34,100
• Sector: Healthcare
• Sector Strength: 38
• Industry: Drug Manufacturers - General
• EPS (TTM): 1.46
• Shares Outstanding: 0
• 10 Day Avg. Volume: 15,006,367
• 30 Day Avg. Volume: 13,263,550
• PEG Ratio: 0.06
• Price to Book (P/B): 7.02
• Price to Sales (P/S): 2.37
• P/FCF Ratio: 8.22
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $51.63
• Price Target Upside: 12.61% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 20

• Rating: 67 Neutral
• Price Target: $47.00 ▲(2.51% Upside)

Bristol-Myers Squibb's overall stock score of 67 reflects strong financial performance and positive earnings call sentiment, offset by bearish technical indicators and some valuation concerns. The company's ability to manage liabilities and stabilize earnings will be crucial for future performance.

Positive Factors

Financial Performance

Bristol-Myers Squibb reported a meaningful beat on the topline and EPS, with both Growth and Legacy portfolios contributing to the beat.

Future Outlook

Guidance for FY25 revenue was raised by $700 million, indicating strong future performance expectations.

Negative Factors

Clinical Trials

The timeline for Cobenfy’s Alzheimer’s Disease Psychosis trial could be impacted by internal reviews, with top-line data expected later than initially anticipated.

Earnings Quality

Concerns remain around the quality of the earnings beat, particularly the reliance on lower quality items such as legacy products, FX, and stocking.

Revenue Projections

The price target for Bristol-Myers Squibb was lowered from $55 to $53 due to reduced long-term projections for certain drugs.

Bristol-Myers Squibb Business Overview & Revenue Model

Company Description

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

How the Company Makes Money

Bristol-Myers Squibb generates revenue primarily through the sale of its pharmaceutical products. The company's revenue model is centered around the development, marketing, and distribution of prescription medicines that address areas with significant unmet medical needs. Key revenue streams include its blockbuster drugs in oncology, such as Opdivo and Yervoy, which are used in cancer treatment, and Eliquis, a leading anticoagulant. Additionally, the company invests heavily in research and development to expand its pipeline of potential new medicines. Partnerships and collaborations with other pharmaceutical companies and research institutions also play a significant role in BMY's revenue generation, enhancing its capabilities in drug discovery and commercialization. Furthermore, strategic acquisitions and alliances help Bristol-Myers Squibb maintain a competitive edge in the biopharmaceutical industry.

Bristol-Myers Squibb Financial Statement Overview

Summary

Bristol-Myers Squibb demonstrates resilient financial performance with significant strengths in cash flow generation and gross profitability. However, net income variability and increased leverage pose potential risks. Continued focus on stabilizing earnings and managing liabilities will be crucial for sustained financial health.

Income Statement

The income statement reveals a stable performance with gross profit margins consistently strong around 70%. However, the net profit margin has fluctuated significantly, with a notable loss in 2024. Revenue growth has been stable, with a slight decline in recent periods. The EBIT and EBITDA margins are solid for the TTM, reflecting efficient cost management despite earlier fluctuations.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, indicating a balanced approach to leveraging. The equity ratio has decreased over time, suggesting an increase in liabilities relative to assets. Return on equity has varied, impacted by fluctuating net income, with a recent improvement in profitability contributing positively.

Cash Flow

Cash flow analysis is favorable, with strong and improving free cash flow, highlighting efficient cash generation. The operating cash flow to net income ratio indicates robust cash conversion efficiency, although historical net income volatility presents some risk. Free cash flow growth is positive, supporting a strong cash position.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	47.64B	48.30B	45.01B	46.16B	46.38B	42.52B
Gross Profit	28.18B	27.43B	25.36B	26.49B	26.76B	21.70B
EBITDA	16.20B	3.17B	19.37B	19.22B	20.12B	4.93B
Net Income	5.42B	-8.95B	8.03B	6.33B	6.99B	-8.99B
Balance Sheet
Total Assets	92.43B	92.60B	95.16B	96.82B	109.31B	118.48B
Cash, Cash Equivalents and Short-Term Investments	11.78B	10.86B	12.28B	9.25B	17.22B	16.45B
Total Debt	51.24B	51.20B	41.46B	40.72B	45.60B	51.67B
Total Liabilities	74.98B	76.22B	65.67B	65.70B	73.31B	80.60B
Stockholders Equity	17.39B	16.34B	29.43B	31.06B	35.95B	37.82B
Cash Flow
Free Cash Flow	13.09B	13.94B	12.65B	11.95B	15.23B	13.30B
Operating Cash Flow	14.31B	15.19B	13.86B	13.07B	16.21B	14.05B
Investing Cash Flow	-2.23B	-21.35B	-2.29B	-1.06B	-538.00M	-10.86B
Financing Cash Flow	-10.51B	5.13B	-9.42B	-16.96B	-16.22B	-1.15B

Bristol-Myers Squibb Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 45.85
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMY, the sentiment is Negative. The current price of 45.85 is below the 20-day moving average (MA) of 46.98, below the 50-day MA of 47.11, and below the 200-day MA of 52.40, indicating a bearish trend. The MACD of -0.52 indicates Positive momentum. The RSI at 45.96 is Neutral, neither overbought nor oversold. The STOCH value of 34.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BMY.

Bristol-Myers Squibb Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MRK	79 Outperform	$199.10B	12.22	39.31%	4.04%	2.01%	―
GSK	74 Outperform	$74.84B	17.29	23.04%	4.27%	3.46%	-13.29%
SNY	73 Outperform	$0.00	11.95	8.39%	4.62%	-9.32%	120.62%
GILD	71 Outperform	$139.89B	24.08	32.51%	2.77%	4.63%	1144.01%
BMY	67 Neutral	$0.00	18.32	29.31%	5.37%	2.57%	―
PFE	66 Neutral	$140.71B	12.51	12.16%	6.91%	13.38%	―
Sector *	51 Neutral	$7.38B	0.52	-67.26%	2.36%	16.67%	-0.20%

Bristol-Myers Squibb Corporate Events

Bristol-Myers Squibb Q2 2025 Financial Results Released

On July 31, 2025, Bristol Myers Squibb reported its financial results for the second quarter of 2025, highlighting a total revenue of $12.3 billion, a 1% increase from the previous year. The company’s Growth Portfolio revenues rose by 18%, driven by strong performances in its immuno-oncology products, while the Legacy Portfolio saw a decline due to generic competition and Medicare Part D impacts. The company raised its 2025 revenue guidance and emphasized its focus on advancing transformational medicines and pipeline opportunities to sustain long-term growth.

The most recent analyst rating on (BMY) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on Bristol-Myers Squibb stock, see the BMY Stock Forecast page.

Bristol-Myers Squibb Appoints New Chief Medical Officer

On July 25, 2025, Bristol Myers Squibb announced the departure of Dr. Samit Hirawat, the Chief Medical Officer and Head of Development, effective November 1, 2025. Dr. Hirawat will transition to an advisory role starting August 1, 2025, and will receive severance benefits and prorated incentives. Concurrently, Dr. Cristian Massacesi will join the company as the new Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025. Dr. Massacesi brings extensive experience from his previous roles at AstraZeneca and Alexion, and his appointment is expected to bolster Bristol Myers Squibb’s efforts in advancing its product pipeline and achieving regulatory approvals.

The most recent analyst rating on (BMY) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on Bristol-Myers Squibb stock, see the BMY Stock Forecast page.

Bristol-Myers Squibb Holds Annual Shareholder Meeting 2025

On May 6, 2025, Bristol-Myers Squibb held its Annual Meeting, where shareholders elected 11 directors to serve until the 2026 meeting. Key decisions included the approval of executive compensation and the ratification of Deloitte & Touche LLP as the independent accounting firm for 2025. However, shareholder proposals on Corporate Financial Sustainability and ceasing DEI efforts were not approved.